|
Novartis announces an exclusive global licensing and research collaboration with Regenerex
|
06 September 2013 |
|
Novartis holds annual healthcare entrepreneur competition
|
28 August 2013 |
|
Novartis first company accredited with global CEO Cancer Gold Standard
|
11 August 2013 |
|
Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
|
07 August 2013 |
|
Novartis delivered growth across all divisions in second quarter
|
22 July 2013 |
|
Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
|
08 July 2013 |
|
Novartis launches a new campaign to raise awareness of MS
|
29 May 2013 |
|
Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
|
12 May 2013 |
|
Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
|
08 May 2013 |
|
Novartis delivered solid performance in the first quarter
|
24 April 2013 |